Sunshine Biopharma Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 9, 2021 and accepted by EDGAR at Aug 9, 2021, 12:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $52.9k | us-gaap:Revenues |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $92.9k | us-gaap:Revenues |
| Cost of revenue | 3 months2021-04-01 to 2021-06-30 | $18.5k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2021-01-01 to 2021-06-30 | $37.0k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2021-04-01 to 2021-06-30 | $34.4k | us-gaap:GrossProfit |
| Gross profit | 6 months2021-01-01 to 2021-06-30 | $55.9k | us-gaap:GrossProfit |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $191.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $358.5k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$388.6k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-04-01 to 2021-06-30 | $195.6k | us-gaap:InterestExpense |
| Interest expense | 6 months2021-01-01 to 2021-06-30 | $245.3k | us-gaap:InterestExpense |
| Income tax | 3 months2021-04-01 to 2021-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-01-01 to 2021-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$2.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$9.1m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2021-04-01 to 2021-06-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-01 to 2021-06-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$916.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-06-30 | $1.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $1.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $1.8m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $635.6k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $2.7m | us-gaap:Liabilities |
| Long-term debt | At period end2021-06-30 | $2.1m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2021-06-30 | −$872.7k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001683168-21-003345. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.